LivaNova PLC (LIVN)
| Market Cap | 3.95B +99.9% |
| Revenue (ttm) | 1.43B +12.4% |
| Net Income | 107.15M |
| EPS | 1.94 |
| Shares Out | 54.93M |
| PE Ratio | 36.99 |
| Forward PE | 16.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 901,298 |
| Open | 71.25 |
| Previous Close | 70.93 |
| Day's Range | 70.32 - 72.51 |
| 52-Week Range | 41.02 - 72.51 |
| Beta | 0.82 |
| Analysts | Buy |
| Price Target | 76.29 (+6.17%) |
| Earnings Date | May 6, 2026 |
About LIVN
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing sy... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for LIVN stock is "Buy." The 12-month stock price target is $76.29, which is an increase of 6.17% from the latest price.
News
LivaNova price target lowered to $76 from $78 at Baird
Baird lowered the firm’s price target on LivaNova (LIVN) to $76 from $78 and keeps an Outperform rating on the shares.The firm updated its model following beat and raise Q1
LivaNova price target raised to $90 from $85 at Mizuho
Mizuho raised the firm’s price target on LivaNova (LIVN) to $90 from $85 and keeps an Outperform rating on the shares.
LivaNova price target raised to $76 from $73 at Barclays
Barclays raised the firm’s price target on LivaNova (LIVN) to $76 from $73 and keeps an Equal Weight rating on the shares.
LivaNova reports Q1 adjusted EPS 98c, consensus 90c
Reports Q1 revenue $362.3M, consensus $346.11M. “In the first quarter, LivaNova (LIVN) delivered double-digit revenue growth with strength across all regions, driven by sustained performance in our Ca...
LivaNova raises FY26 adjusted EPS view to $4.20-$4.30 from $4.15-$4.25
FY26 consensus $4.21. LivaNova (LIVN) now expects full-year 2026 revenue to grow between 7.0% and 8.0% (versus 6.0% and 7.0% prior) on a constant-currency basis. Foreign currency is expected to
LivaNova Earnings Call Transcript: Q1 2026
Q1 2026 saw 11% revenue growth, driven by strong cardiopulmonary and epilepsy performance, with upgraded full-year guidance reflecting robust demand and key regulatory milestones in OSA. Adjusted EPS and revenue outlooks were raised, and capital investments continue to support expansion.
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2026 and raised full-year...
Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal Medicine has published an article...
LivaNova to Announce First-Quarter 2026 Results
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, ...
LivaNova granted premarket approval for aura6000 System by FDA
LivaNova (LIVN) announced the FDA granted premarket approval for the aura6000 System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea. The System utilizes proximal h...
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted premarket approva...
LivaNova price target raised to $73 from $67 at Barclays
Barclays raised the firm’s price target on LivaNova (LIVN) to $73 from $67 and keeps an Equal Weight rating on the shares. The firm cites the company’s Q4 beat for
LivaNova price target raised to $83 from $75 at Baird
Baird raised the firm’s price target on LivaNova (LIVN) to $83 from $75 and keeps an Outperform rating on the shares. The firm updated its model following results which suggests
LivaNova price target raised to $85 from $72 at Mizuho
Mizuho raised the firm’s price target on LivaNova (LIVN) to $85 from $72 and keeps an Outperform rating on the shares. The firm views the company’s 2026 outlook as solid.
LivaNova price target raised to $73 from $66 at Goldman Sachs
Goldman Sachs analyst David Roman raised the firm’s price target on LivaNova (LIVN) to $73 from $66 and keeps a Neutral rating on the shares. LivaNova delivered another year of
LivaNova price target raised to $80 from $70 at Stifel
Stifel raised the firm’s price target on LivaNova (LIVN) to $80 from $70 and keeps a Buy rating on the shares after both key divisions, neuromodulation and cardiopulmonary, delivered “better-than-expe...
LivaNova Earnings Call Transcript: Q4 2025
Delivered double-digit revenue and EPS growth in 2025, driven by strong cardiopulmonary and epilepsy performance, expanded margins, and robust cash flow. 2026 guidance calls for 6%-7% revenue growth, continued innovation, and disciplined capital allocation.
LivaNova sees FY26 adjusted EPS $4.15-$4.25, consensus $4.13
LivaNova (LIVN) sees FY26 revenue up 6.0%-7.0% on a constant-currency basis. Foreign currency is expected to be a tailwind of approximately 1.0% based on current exchange rates. FY26 adjusted EPS
LivaNova reports Q4 djusted EPS 86c, consensus 81c
Reports Q4 revenue $360.9M, consensus $354.31M. “In 2025, LivaNova (LIVN) delivered double-digit revenue growth, meaningful operating margin expansion, and robust cash generation, reflecting strong ex...
LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2025 results and issued full-year 2026 gui...
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2025 results o...
LivaNova Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company is executing a two-phase growth strategy, leveraging core strengths in cardiopulmonary and epilepsy to enter the high-growth OSA market, supported by strong clinical data and recent reimbursement gains. OSA commercialization is staged, with profitability expected by 2029 and significant margin expansion by 2030.
LivaNova price target raised to $67 from $58 at Barclays
Barclays raised the firm’s price target on LivaNova (LIVN) to $67 from $58 and keeps an Equal Weight rating on the shares. The firm cites an increased target multiple, in
LivaNova price target raised to $66 from $56 at Goldman Sachs
Goldman Sachs analyst David Roman raised the firm’s price target on LivaNova (LIVN) to $66 from $56 and keeps a Neutral rating on the shares. After a year when fundamentals
LivaNova price target raised to $70 from $65 at Stifel
Stifel raised the firm’s price target on LivaNova (LIVN) to $70 from $65 and keeps a Buy rating on the shares. The firm, which argues that the 2026 setup is